Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Simoctocog alfa for the treatment of patients with hemophilia A

Susan Halimeh • 11 Jul 2022
ISTH 2022
Hemophilia Simoctocog alfa

Susan Halimeh, MD, Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany, briefly comments on the efficacy of simoctocog alfa, a novel recombinant FVIIII with an extended half-life, in previously treated patients with hemophilia A. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Susan Halimeh

1:09
Highlights from ISTH: gene therapy in hemophilia A & undiagnosed bleeding disorders in pediatrics
Susan Halimeh • 11 Jul 2022
0:51
Intramuscular COVID-19 vaccination in patients with severe hemophilia A
Susan Halimeh • 11 Jul 2022
0:59
Managing pregnant women with vWD
Susan Halimeh • 11 Jul 2022
1:23
Challenges in vWD: new guidelines & managing women with vWD
Susan Halimeh • 12 Jul 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals